Table 1_Exploring the celecoxib–cervical cancer relationship using in vitro, network pharm

Tongfei Wang published a pharmacological study on figshare in May 2026. The dataset integrates in vitro experiments, network pharmacology, and Mendelian randomization analyses to explore the anticancer role of celecoxib against cervical cancer. It includes results on cell proliferation inhibition and causal inference linking NEU1 inhibition to reduced cancer risk.

Use Cases

• Validate drug efficacy hypotheses based on in vitro assay results for cervical cancer cell lines.
• Identify potential drug targets and pathways using network pharmacology analysis.
• Perform causal inference analysis on drug-target relationships using Mendelian randomization results.
• Investigate immune cell mediation effects based on the reported CD25 on CD45RA+ CD4+ non-regulatory T cell data.

Strengths

• Integrates multiple methodological approaches: in vitro assays, network pharmacology, and Mendelian randomization.
• Provides specific causal inference results, including an odds ratio (OR = 0.736) and mediation percentage (28.458%).
• Dataset is openly licensed under CC-BY-4.0.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (13.6 KB), suggesting limited scope or summary-level data.

Provenance

Source

figshare

Collection Method

Combined in vitro experiments, computational network pharmacology, and genetic Mendelian randomization analysis.

Freshness

Last updated 2026-05-19 05:40:27; freshness should be verified.